The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | The evolving treatment landscape of R/R FL & the importance of individualizing treatment approaches
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discusses advances that have been made in the treatment landscape of relapsed/refractory (R/R) follicular lymphoma (FL), highlighting novel agents including mosunetuzumab and tazemetostat. Dr Patel also comments on the importance of individualizing treatment approaches and selecting the best option for each patient. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant or advisory role: Abbvie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou Biosciences, Celgene, Epizyme, Genentech/Roche, Kite, Loxo Oncology, MEI Pharma, Morphosys, Pharmacyclics/Janssen, TG Therapeutics, Trillium Therapeutics/Pfizer, Xencor
Research funding: Adaptive Biotechnologies, Aptevo Therapeutics, AstraZeneca, Bristol Myers Squibb, CRISPR Therapeutics, Celgene, Curis, Inc, Epizyme, Fate Therapeutics, Genentech/Roche, Kite, Loxo Oncology, MEI Pharma, Nurix, Pharmacyclics/Janssen, Sunesis, Pharmaceuticals, Trillium Therapeutics/Pfizer, Velos Bio, Xencor
